

# ESMO ADVANCED COURSE PROGRAMME ADC DEVELOPMENT, THERAPEUTIC APPLICATIONS AND RESEARCH: THORACIC AND GENITOURINARY CANCERS

Singapore  
9-10 October 2024

---

**CHAIRS** Ravindran Kanesvaran, Singapore  
Solange Peters, Switzerland

**SPEAKERS** Aaron R. Hansen, Australia  
Nye-Thane Ngo, Singapore  
David Planchard, France  
Darren M. C. Poon, Hong Kong SAR, China  
Egbert F. Smit, The Netherlands  
Tira J. Y. Tan, Singapore  
Kelvin C. K. Yan, Hong Kong SAR, China

---

## LEARNING OBJECTIVES

- To provide insights on ADCs drug development
- To explain the mechanism of action of the most common ADCs used in clinical practice
- To highlight the integration of ADCs in current clinical practice guidelines across pathologies
- To provide guidance on management of toxicities of ADCs

---

## ACCREDITATION

The programme of this event has been accredited with **8 ESMO-MORA category 1 points**.  
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

## ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4, 6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Wednesday, 9 October 2024

---

### 09:00-09:10 **Welcome and introduction**

10' Welcome and Learning Objectives Introduction  
Ravindran Kanesvaran, SG and Solange Peters, CH

### 09:10-10:40 **Session 1 – ADC Development and pharmacodynamics** **Chair: Ravindran Kanesvaran, SG**

20' Mechanisms of action and resistance: ADC internalization and cleavage and mechanisms of resistance  
Aaron R. Hansen, AU

20' Toxicity: Prediction, identification and treatment  
Tira J. Y. Tan, SG

20' ADC development: What are the considerations in early phase trials?  
David Planchard, FR

30' Discussion

### *10:40-11:10 Coffee break*

### 11:10-11:45 **Session 2 – Target assessment and rationale for combinations** **Chair: Solange Peters, CH**

20' Considerations from pathology: Biomarker selection, on-target off-tumour expression of target toxicities  
Nye-Thane Ngo, SG

15' Discussion

### *11:45-13:00 Lunch*

### 13:00-14:30 **Session 3 – Next generation ADCs** **Chair: Ravindran Kanesvaran, SG**

20' Developments in ADC constructs including: Bispecific ADCs,  
Egbert F. Smit, NL

20' Additional innovative strategies: Cytokine conjugates, peptide-based conjugates  
Darren M. C. Poon, HK SAR, CN

20' How to develop rationale combinations and sequencing  
Kelvin C. K. Yan, HK SAR, CN

30' Discussion

### *19:00 Networking dinner*

## Thursday, 10 October 2024

---

09:00-12:30

### Workshop sessions

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotational basis)

15' Introduction based on clinical cases presented by speakers

40' Discussion

5' Break

#### Workshop 1

ADC trials in GU (bladder cancer)

Ravindran Kanesvaran, SG

Darren M. C. Poon, HK SAR, CN

#### Workshop 2

ADC trials in thoracic cancers

Solange Peters, CH

Egbert F. Smit, NL

#### Workshop 3

ADC related toxicities

David Planchard, FR

Tira J. Y. Tan, SG

*11:00-11:30*

*Coffee break*

11:30-12:30

### Workshops continuation

12:30-13:00

### Feedback on the workshops from each group

13:00-13:15

### Synthesis and wrap-up

Ravindran Kanesvaran, SG and Solange Peters, CH

*13:15-14:15*

*Lunch*